Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-004730-42
    Sponsor's Protocol Code Number:IQVIA-ODYS-001-LZA45541
    National Competent Authority:France - ANSM
    Clinical Trial Type:EEA CTA
    Trial Status:Trial now transitioned
    Date on which this record was first entered in the EudraCT database:2021-12-21
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedFrance - ANSM
    A.2EudraCT number2019-004730-42
    A.3Full title of the trial
    Prospective evaluation of potential effects of repeated gadolinium-based contrast agent (GBCA) administrations of the same GBCA on motor and cognitive functions in neurologically normal adults in comparison to a non-GBCA exposed control group—ODYSSEY
    Évaluation prospective des effets potentiels d’administrations répétées d’un même produit de contraste à base de gadolinium (PCBG) sur les fonctions motrices et cognitives chez des adultes normaux sur le plan neurologique par rapport à une cohorte témoin non exposée à un PCBG – ODYSSEY
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    Long-term impact of GBCAs on motor and cognitive function following repeated Contrast-Enhanced MRI—ODYSSEY.
    Impact à long terme des PCBG sur la fonction motrice et cognitive après des IRM avec produit de contraste répétés - Étude ODYSSEY.
    A.4.1Sponsor's protocol code numberIQVIA-ODYS-001-LZA45541
    A.5.2US NCT (ClinicalTrials.gov registry) numberNCT04373564
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorIQVIA RDS FRANCE SAS
    B.1.3.4CountryFrance
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportBayer AG
    B.4.2CountryGermany
    B.4.1Name of organisation providing supportBracco Imaging S.p.A.
    B.4.2CountryItaly
    B.4.1Name of organisation providing supportGE Healthcare Pharma LLC
    B.4.2CountryUnited States
    B.4.1Name of organisation providing supportGuerbet
    B.4.2CountryFrance
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationIQVIA RDS FRANCE SAS
    B.5.2Functional name of contact pointClinical Trial Information
    B.5.3 Address:
    B.5.3.1Street AddressTour D2 /17 Bis Place des Reflets /TSA 64567
    B.5.3.2Town/ cityLa Défense Cedex
    B.5.3.3Post code92099
    B.5.3.4CountryFrance
    B.5.6E-mailsCRO.ODYSSEY@iqvia.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name MultiHance
    D.2.1.1.2Name of the Marketing Authorisation holderBracco S.p.A.
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameMultiHance
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGADOBENATE DIMEGLUMINE
    D.3.9.3Other descriptive nameGADOBENATE DIMEGLUMINE
    D.3.9.4EV Substance CodeSUB20638
    D.3.10 Strength
    D.3.10.1Concentration unit mmol/kg millimole(s)/kilogram
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.05
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name DOTAREM® (gadoterate meglumine) Injection for intravenous use
    D.2.1.1.2Name of the Marketing Authorisation holderGUERBET LLC
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameDOTAREM® (gadoterate meglumine) Injection for intravenous use
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNMEGLUMINE GADOTERATE
    D.3.9.3Other descriptive nameMEGLUMINE GADOTERATE
    D.3.9.4EV Substance CodeSUB03121MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mmol/kg millimole(s)/kilogram
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.2
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name ProHance (gadoteridol injection)
    D.2.1.1.2Name of the Marketing Authorisation holderBracco
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameProHance
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGADOTERIDOL
    D.3.9.1CAS number 120066-54-8
    D.3.9.3Other descriptive nameGADOTERIDOL
    D.3.9.4EV Substance CodeSUB07866MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mmol/kg millimole(s)/kilogram
    D.3.10.2Concentration typerange
    D.3.10.3Concentration number0.1 to 0.3
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 4
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Gadovist
    D.2.1.1.2Name of the Marketing Authorisation holderBayer AG
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGadovist
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGADOBUTROL
    D.3.9.1CAS number 138071-82-6
    D.3.9.3Other descriptive nameGADOBUTROL
    D.3.9.4EV Substance CodeSUB07861MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mmol/ml millimole(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1.0
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 5
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Gadovist
    D.2.1.1.2Name of the Marketing Authorisation holderBayer AG
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameGadovist
    D.3.4Pharmaceutical form Solution for injection in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGADOBUTROL
    D.3.9.1CAS number 138071-82-6
    D.3.9.3Other descriptive nameGADOBUTROL
    D.3.9.4EV Substance CodeSUB07861MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mol/ml mole(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 6
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Primovist
    D.2.1.1.2Name of the Marketing Authorisation holderBayer AG
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePrimovist
    D.3.4Pharmaceutical form Solution for injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGADOXETIC ACID, DISODIUM
    D.3.9.3Other descriptive nameGADOXETIC ACID, DISODIUM
    D.3.9.4EV Substance CodeSUB39501
    D.3.10 Strength
    D.3.10.1Concentration unit mmol/ml millimole(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 7
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.1.1Trade name Primovist
    D.2.1.1.2Name of the Marketing Authorisation holderBayer AG
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product namePrimovist
    D.3.4Pharmaceutical form Solution for infusion in pre-filled syringe
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNGADOXETIC ACID, DISODIUM
    D.3.9.3Other descriptive nameGADOXETIC ACID, DISODIUM
    D.3.9.4EV Substance CodeSUB39501
    D.3.10 Strength
    D.3.10.1Concentration unit mmol/ml millimole(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number0.25
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Long term potential effect of repeated exposure to either a linear or a macrocyclic gadolinium-based contrast agent (GBCA) on change from baseline to Year 5 in motor and cognitive function among neurologically normal adults in comparison to a matched non-GBCA–exposed control group effects regarding
    Effets potentiels à long terme d’administrations répétées d’un même produit de contraste à base de gadolinium (PCBG) sur le changement entre le référence et l'année 5 des fonctions motrices et cognitives chez des adultes normaux sur le plan neurologique par rapport à une cohorte témoin non exposée à un PCBG
    E.1.1.1Medical condition in easily understood language
    Prospective evaluation of potential effects of repeated gadolinium-based contrast agent administrations
    Évaluation prospective des effets potentiels d’administrations répétées d’un même produit de contraste à base de gadolinium
    E.1.1.2Therapeutic area Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Diagnosis [E01]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10070999
    E.1.2Term Intraductal papillary mucinous neoplasm
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10006187
    E.1.2Term Breast cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.1
    E.1.2Level LLT
    E.1.2Classification code 10008953
    E.1.2Term Chronic liver disease
    E.1.2System Organ Class 100000004871
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.0
    E.1.2Level PT
    E.1.2Classification code 10061451
    E.1.2Term Colorectal cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10060862
    E.1.2Term Prostate cancer
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To prospectively assess the potential effect of repeated exposure to either a linear or a macrocyclic gadolinium-based contrast agent (GBCA) on change from baseline to Year 5 in motor and cognitive function among neurologically normal adults in comparison to a matched non-GBCA–exposed control group.
    Évaluer de manière prospective l’effet potentiel d’une exposition répétée à un produit de contraste à base de gadolinium (PCBG) soit linéaire, soit macrocyclique sur la variation de la fonction motrice et cognitive entre la référence et l’Année 5 chez des adultes normaux sur le plan neurologique par rapport à une cohorte témoin appariée qui n’a pas été exposée aux PCBG.
    E.2.2Secondary objectives of the trial
    • To assess the change from baseline in the composite endpoints (motor and cognitive) at each of the post-baseline time points (Years 1 to 4) in GBCA-exposed participants as compared to controls.
    • To assess the change from baseline for each of the individual tests (motor and cognitive) at each of the post-baseline time points (Years 1 to 5) in GBCA-exposed participants as compared to controls.
    • To evaluate safety through collection of adverse events.
    • To assess total Gd concentrations (as measured in a central laboratory) in blood and urine samples taken from exposed and control participants at the time of annual visit.
    • Évaluer la variation par rapport à la référence au niveau des critères d’évaluation composites (moteurs et cognitifs) à chacun des points temporels post-référence (Années 1 à 4) chez les participants exposés à un PCBG par rapport aux témoins.

    • Évaluer la variation par rapport à la référence de chacun des tests individuels (moteurs et cognitifs) à chacun des points temporels post-référence (Années 1 à 5) chez les participants exposés à un PCBG par rapport aux témoins.

    • Évaluer la sécurité d’emploi en recueillant les effets indésirables.

    • Évaluer les concentrations totales de Gd (mesurées dans un laboratoire central) dans les échantillons de sang et d’urine prélevés chez les participants exposés et chez les patients témoins lors de la visite annuelle.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Participant must be an adult having reached legal majority age and less than 65 years old.
    2. Participant must be neurologically normal, defined as free of unstable neurologic and psychiatric disease as confirmed by a normal neurologic examination at screening.
    3. Participant agrees to be tested as per protocol for 5 consecutive years
    4. Participant (GBCA-exposed or controls) agrees to undergo unenhanced magnetic resonance imaging (UE-MRI) of the brain at enrollment and at the end of the observation period (5 years).
    5. Patient affiliated to national health insurance according to local regulatory requirements, where applicable.
    6. Participants should have at least 1 of the following indications:
    • Medium to high risk for breast cancer or dense breasts undergoing breast cancer screening with MRI.
    • Elevated prostate-specific antigen (PSA) and under active diagnostic surveillance for prostate cancer.
    • Chronic liver disease (eg, liver cirrhosis limited to Child class A, post-hepatitis chronic hepatopathy, or primary sclerosing cholangitis) for surveillance of hepatocellular carcinoma development.
    • Low-grade colorectal cancer or neuroendocrine tumor undergoing screening for liver metastases.
    • Branch-duct intraductal papillary mucinous neoplasm (IPMN) of the pancreas (maximum size ≤2 cm) undergoing imaging surveillance.

    In addition, for participants in the GBCA Arms only:
    7. Each participant should be likely to undergo ≥5 GBCA-enhanced MR examinations with the same GBCA at least annually throughout the 5-year study duration.
    8. Prospective participants with up to 3 well-documented GBCA administrations prior to study screening are acceptable, provided that the imaging was performed with the same GBCA as the one to be prospectively used in the study. If the GBCA used cannot be identified, he/she cannot be enrolled.

    For the Control Arm:
    9. Participants who never had and are not likely to receive any GBCA injection during the course of the study.
    10. Each control participant must be willing to undergo UE-MRI of the brain at baseline and at Year 5. In Years 1 to 4, the control participants will undergo their clinically indicated UE-MRIs, computed tomography (CT), ultrasound, or X-ray procedures.
    11. Participants matched with the population characteristics of the 2 GBCA study arms, including clinical indication for imaging, geographic region, and age-group. Additional potential risk factors (education level and sex) will be recorded and adjusted for as appropriate at the statistical analysis stage.



    1. Le participant doit être un adulte ayant atteint l’âge de la majorité légale et âgé de moins de 65 ans.
    2. Le participant doit être normal sur le plan neurologique, c’est-à-dire exempt de maladie neurologique et psychiatrique instable, comme confirmé par un examen neurologique normal à la sélection.
    3. Le participant accepte de faire l’objet de tests conformément au protocole pendant 5 années consécutives
    4. Le participant (exposé à un PCBG ou témoin) accepte d’effectuer une imagerie par résonance magnétique non rehaussée (IRM-NR) du cerveau à l’inclusion et à la fin de la période d’observation (5 ans).
    5. Patient affilié à l’assurance maladie nationale conformément aux exigences réglementaires locales, le cas échéant.
    6. Les participants doivent présenter au moins l’une des indications suivantes :

    • Risque moyen à élevé de cancer du sein ou de densité mammaire faisant l’objet d’un dépistage du cancer du sein par IRM.
    • Taux élevé d’antigène prostatique spécifique (PSA) et patient sous surveillance diagnostique active pour le cancer de la prostate.
    • Maladie hépatique chronique (par ex. cirrhose hépatique limitée à la classe A de Child, hépatopathie chronique post-hépatite ou cholangite sclérosante primitive) entraînant la surveillance du développement d’un carcinome hépatocellulaire.
    • Cancer colorectal de bas grade ou tumeur neuroendocrine en cours de dépistage pour rechercher des métastases hépatiques.
    • Néoplasme intracanalaire papillaire et mucineux (IPMN) du canal pancréatique (taille maximale  2 cm) sous surveillance par imagerie.
    En outre, pour les participants des bras PCBG uniquement :
    7. Chaque participant doit être susceptible de faire l’objet de  5 examens par RM rehaussés au PCBG, en utilisant le même PCBG, au moins une fois par an pendant les 5 ans de l’étude.
    8. Les participants potentiels ayant reçu jusqu’à 3 administrations de PCBG bien documentées avant la sélection de l’étude sont acceptables, à condition que l’imagerie ait été réalisée avec le même PCBG que celui qui sera utilisé de manière prospective dans l’étude. Si le PCBG utilisé ne peut pas être identifié, le patient ne peut pas être inclus.
    Pour le bras témoin :
    9. Participants n’ayant jamais reçu, et n’étant pas susceptibles de recevoir, une injection de PCBG au cours de l’étude.
    10. Chaque participant témoin doit être disposé à subir une IRM-NR du cerveau à la référence et à l’Année 5. Aux Années 1 à 4, les participants témoins feront l’objet d’IRM-NR, de tomodensitométries (TDM), d’échographies ou de radiographies comme cliniquement indiquées.
    11. Participants appariés selon les caractéristiques de population des 2 bras PCBG de l’étude, y compris l’indication clinique pour l’imagerie, la région géographique et la tranche d’âge. Des facteurs de risque potentiels supplémentaires (niveau d’éducation et sexe) seront enregistrés et ajustés selon le cas au stade de l’analyse statistique.
    E.4Principal exclusion criteria
    Patients are excluded from the study if any of the following criteria apply:
    1. As evidenced by history or determined in the neurologic exam at screening, concurrent neurological and/or psychiatric disease (or treatments) that could influence the results of the study’s motor and cognitive tests. Examples include but are not limited to:
    • Cerebrovascular disease.
    • Multiple sclerosis.
    • Neurodegenerative disease.
    • Malignant disease other than listed in indications.
    • Carcinoid tumors.
    • Epilepsy.
    • Prior neurosurgery.
    • Psychotic disorders or any prior psychotic episode not otherwise specified (NOS)—any documented prior history of chronic schizophrenia.
    • Remittent or current medically confirmed major depressive disorder or bipolar disorder.
    • History of long-term major depression or bipolar affective disorder with an active episode in the past 2 to 5 years.
    • Neurodevelopmental disorders (eg, trisomy 21).
    • Uncontrolled severe migraine.
    • Uncontrolled or controlled anxiety or depression within 6 months before enrollment.
    • Screening scores of ≤24 on the MMSE and/or ≥11 on the Hospital Anxiety and Depression Scale (HADS).
    2. Prior, planned, or ongoing chemotherapy or brain irradiation
    3. Use of concomitant medication(s) affecting neuro-cognitive or motor function (an authorized exception is a single intake before the study MRI because of anxiety if administered after the motor and cognitive test evaluation):
    • Regular use of benzodiazepines or non-benzodiazepine hypnotics. Long-acting benzodiazepines (eg, diazepam) should not be administered within 24 hours prior to cognitive testing.
    • Short/medium-acting benzodiazepines (eg, alprazolam, lorazepam, oxazepam, temazepam), except if used chronically for sleep and on a stable dose for 8 weeks prior to Screening Visit 1 or 12 hours prior to cognitive testing.
    • Regular use of anticholinergic drugs (anticholinergics for bladder control with limited cognitive effects are permitted).
    • Long-term use of corticosteroids or methotrexate, cladribine.
    • Regular use of antidepressants (eg, anticholinergic, tricyclic, monoamine oxidase inhibitors (MAOIs), norepinephrine–dopamine reuptake inhibitors (NDRIs) selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), or lithium, anti-epileptics and/or antipsychotic drugs: Use of antidepressants is allowed if at stable doses for 8 weeks prior to Screening Visit. Antipsychotics used on a regular basis, except for low doses of atypical antipsychotics (e.g., risperidone, aripiprazole, or quetiapine), anticonvulsants with limited cognitive effects, such as lamotrigine, pregabalin, levetiracetam for treatment of pain, and other non-epilepsy indications, are allowed as-needed basis or if used at a stable dose for 8 weeks prior to Screening Visit
    • CNS stimulants (eg, for attention-deficit/hyperactivity disorder [ADHD])
    4. Substance or alcohol abuse as determined by the investigator.
    5. Alcoholic cirrhosis.
    6. Any history or presence of other relevant chronic disease that prevents participation in the study or that may confound neurofunction testing.
    7. Renal disease, defined as estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2, calculated by using the Modification of Diet in Renal Disease (MDRD) formula or the Kidney Disease Epidemiology Collaboration (CKD-EPI) equation.
    8. History of environmental/occupational/other exposure to one or more chemicals that may affect cognitive and/or motor function, including, but not limited to, heavy metals (arsenic [As], cadmium [Cd], lead [Pb], manganese [Mn], and mercury [Hg]), pesticides, solvents, or carbon monoxide.
    9. Anticipated, current, or past conditions (medical, psychological, social, or geographical) that, in the opinion of the investigator, would compromise the participant’s safety or her/his ability to participate in the study (eg, clinically significant vitamin B12 deficiency, folic acid deficiency, uncontrolled thyroid dysfunction from medical history).
    10. Clinical indications requiring >1 contrast-enhanced magnetic resonance imaging (CE-MRI) every 6 months.
    11. Receipt of any investigational product or participation in any other clinical trial within 30 days prior to enrolling in this study or while enrolled in this trial.
    12. Previous enrollment in this study.
    13. Pregnant or nursing (lactating) women.
    14. Presence of any metal-containing joint implants/prostheses.

    In addition, for participants in either of the GBCA Arms only:
    15. Any contraindication to GBCA-enhanced MRI examinations.
    16. Receipt of a GBCA or generic prior to study entry other than the specific GBCA to be administered during the course of the study.

    In addition, for participants in the Control Arm only:
    17. Participants with any previous exposure to a GBCA.
    18. Participants with any contraindication to UE-MRI examinations.
    1.Maladie neurologique et/ou psychiatrique concomitante (ou traitements) qui pourrait influencer les résultats des tests moteurs et cognitifs de l’étude, comme en témoignent les antécédents ou comme déterminé lors de l’examen neurologique à la sélection. Cela inclut entre autres :
    •Maladie cérébrovasculaire.•Sclérose en plaques.•Maladie neurodégénérative.
    •Maladie maligne autre que celles énumérées dans les indications.•Tumeurs carcinoïdes.•Épilepsie.•Neurochirurgie antérieure.•Troubles psychotiques ou tout épisode psychotique antérieur non spécifié (NS) – tout antécédent documenté de schizophrénie chronique.•Trouble dépressif majeur ou trouble bipolaire en rémission ou en cours, médicalement confirmé.•Antécédents de dépression majeure ou de trouble affectif bipolaire à long terme avec un épisode actif au cours des 2 à 5 dernières années.•Troubles neurodéveloppementaux (par ex. trisomie 21).•Migraine sévère non contrôlée.
    •Anxiété ou dépression non contrôlée ou contrôlée dans les 6 mois précédant l’inclusion.•Scores à la sélection  24 sur le mini examen de la santé mentale (Mini-Mental State Examination, MMSE) et/ou  11 sur l’échelle hospitalière d’anxiété et de dépression (Hospital Anxiety and Depression Scale, HADS).
    2.Chimiothérapie ou irradiation cérébrale antérieure, prévue ou en cours.
    3.Utilisation de médicament(s) concomitant(s) affectant la fonction neurocognitive ou motrice (une exception autorisée est une prise unique avant l’IRM de l’étude en raison de l’anxiété, si administrée après l’évaluation du test moteur et cognitif) :
    •Utilisation régulière de benzodiazépines ou non benzodiazépines hypnotiques.
    •Benzodiazépines à courte/moyenne durée d’action
    •Utilisation régulière de médicaments anticholinergiques (les anticholinergiques pour le contrôle de la vessie qui ont des effets cognitifs limités sont autorisés).
    •Utilisation à long terme de corticoïdes ou méthotrexate, cladribine.
    •Utilisation régulière d’antidépresseurs, d’antiépileptiques et/ou d’antipsychotiques : L’utilisation d’antidépresseurs est autorisée à des doses stables pendant 8 semaines avant la visite de sélection. Les antipsychotiques utilisés régulièrement, à l’exception de faibles doses d’antipsychotiques atypiques (p. ex., rispéridone, aripiprazole ou quétiapine), les anticonvulsivants ayant des effets cognitifs limités, tels que la lamotrigine, la prégabaline, le lévétiracétam pour le traitement de la douleur et d’autres indications autres que l’épilepsie, sont autorisés lorsque nécessaire, ou s’ils sont utilisés à une dose stable pendant 8 semaines avant la Visite de sélection
    •Stimulants du SNC
    4.Alcoolisme ou toxicomanie, tel que déterminé par l’investigateur.

    5.Cirrhose alcoolique.

    6. Tout antécédent ou présence d’une autre maladie chronique pertinente qui empêche la participation à l’étude ou qui pourrait fausser les tests de la fonction neuronale.

    7. Maladie rénale, définie comme un débit de filtration glomérulaire estimé (DFGe) < 60 ml/min/1,73 m2, calculé à l’aide de la modification de l’alimentation dans la maladie rénale (Modification of Diet in Renal Disease, MDRD) ou de l’équation du groupe de Collaboration épidémiologique de l’insuffisance rénale (Kidney Disease Epidemiology Collaboration, CKD-EPI).

    8. Antécédents d’exposition environnementale, professionnelle ou d’autre nature à un ou plusieurs produits chimiques pouvant affecter la fonction cognitive et/ou motrice, y compris, entre autres, les métaux lourds (arsenic [As], cadmium [Cd], plomb [Pb], manganèse [Mn] et mercure [Hg]), les pesticides, les solvants ou le monoxyde de carbone.

    9. Affections anticipées, actuelles ou passées (médicales, psychologiques, sociales ou géographiques) qui, de l’avis de l’investigateur, compromettraient la sécurité du participant ou sa capacité à participer à l’étude (par ex., carence en vitamine B12 cliniquement significative, carence en acide folique, dysfonction thyroïdienne non contrôlée d’après les antécédents médicaux).

    10. Indications cliniques nécessitant > 1 imagerie par résonance magnétique avec produit de contraste (IRM-PC) tous les 6 mois.

    11. Administration de tout produit expérimental ou participation à tout autre essai clinique dans les 30 jours précédant l’inclusion dans cette étude ou pendant que le patient est inclus dans cet essai.

    12. Inclusion antérieure dans cette étude.

    13. Femmes enceintes ou allaitantes.

    14. Présence d’implants/de prothèses articulaires contenant du métal.




    En outre, pour les participants dans l’un des bras PCBG uniquement :
    15. Toute contre-indication aux examens d’IRM rehaussée par PCBG.

    16. Réception d’un PCBG ou d’un générique avant l’entrée dans l’étude autre que le PCBG spécifique devant être administré au cours de l’étude.



    En outre, pour les participants du bras témoin uniquement :

    17. Participants ayant déjà été exposés à un PCBG.

    18. Participants présentant toute contre-indication aux examens par IRM-NR.
    E.5 End points
    E.5.1Primary end point(s)
    The co-primary endpoints are the change from baseline to Year 5 in motor function and in cognitive function as expressed by the composite z score, defined as the weighted sum of the z scores of the individual tests. Since each of these tests is considered equally important, each test will be assigned an equal weight.
    Les critères d’évaluation principaux conjoints sont la variation de la fonction motrice et de la fonction cognitive exprimées par le score z composite, défini comme la somme pondérée des scores z des tests individuels, entre la référence et l’Année 5. Chacun de ces tests étant considéré comme tout aussi important, chaque test se verra attribuer un poids égal.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Baseline to year 5
    De la référence à l’Année 5
    E.5.2Secondary end point(s)
    • Changes from baseline in the composite endpoint (years 1 to 4) and in each individual test of motor and cognitive function (years 1 to 5) will be assessed.
    Additional secondary endpoints include:
    • Evaluation of adverse events. The recording of adverse events (AEs) that occur after the signing of the ICF at Screening, will be done at baseline and at each annual visit. Signs/symptoms, onset date/time, severity, causality, seriousness, treatment and outcome, will be recorded.
    • Total gadolinium concentrations in blood plasma and urine samples collected at baseline and at each annual visit will be determined. If the CE-MRI is obtained at the same visit, the blood and urine samples will be obtained prior to imaging.
    • Les variations par rapport à la référence du critère d’évaluation composite (Années 1 à 4) et de chaque test individuel de la fonction motrice et cognitive (Années 1 à 5) seront évaluées.

    Les critères d’évaluation secondaires supplémentaires comprennent :

    • Évaluation des effets indésirables. L’enregistrement des effets indésirables (EI) survenant après la signature du FCE à la sélection sera effectué à la référence et lors de chaque visite annuelle. Les signes/symptômes, la date/l’heure d’apparition, la sévérité, le lien de causalité, la gravité, le traitement et l’issue seront consignés.

    • Les concentrations totales de gadolinium seront déterminées dans les échantillons de plasma sanguin et d’urine prélevés à la référence et à chaque visite annuelle. Si l’IRM-PC est acquise lors de la même visite, les échantillons de sang et d’urine seront obtenus avant l’examen d’imagerie.
    E.5.2.1Timepoint(s) of evaluation of this end point
    change from baseline in the composite endpoints (motor and cognitive) at each of the post-baseline time points (Years 1 to 4) in GBCA-exposed participants as compared to controls.

    the change from baseline for each of the individual tests (motor and cognitive) at each of the post-baseline time points (Years 1 to 5) in GBCA-exposed participants as compared to controls.
    changement par rapport à la référence dans les paramètres composites (moteurs et cognitifs) à chacun des points dans le temps après la référence(années 1 à 4) chez les participants exposés au GBCA par rapport aux témoins.

    le changement par rapport à la ligne de base pour chacun des tests individuels (moteur et cognitif) à chacun des points dans le temps après la référence (années 1 à 5) chez les participants exposés au GBCA par rapport aux témoins.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy No
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) Yes
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    no exposure to GBCA and not expected to receive over 5 consecutive years
    E.8.2.4Number of treatment arms in the trial3
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned26
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA77
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Brazil
    Canada
    China
    Germany
    Italy
    Korea, Republic of
    Netherlands
    Russian Federation
    Switzerland
    United States
    France
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the study is the completion of the last participant’s last visit (LPLV)
    La fin de l’étude est la fin de la dernière visite du dernier participant
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years5
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years5
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 2076
    F.1.3Elderly (>=65 years) No
    F.1.3.1Number of subjects for this age range: 0
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the database on 2021-12-21. Yes
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state272
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 786
    F.4.2.2In the whole clinical trial 2076
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    None
    Non
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-02-01
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-02-15
    P. End of Trial
    P.End of Trial StatusTrial now transitioned
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 12:38:12 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA